Stockscreener 앱 받기
0.5799
0.57%
-0.000100
전일 마감가:
$0.5798
열려 있는:
$0.6099
하루 거래량:
287.91K
Relative Volume:
0.19
시가총액:
$169.40M
수익:
$54,000
순이익/손실:
$-210.26M
주가수익비율:
-0.7341
EPS:
-0.79
순현금흐름:
$-159.01M
1주 성능:
-1.32%
1개월 성능:
-7.17%
6개월 성능:
-63.51%
1년 성능:
-69.97%
1일 변동 폭
$0.5545
$0.6099
1주일 범위
$0.5545
$0.6522
52주 변동 폭
$0.5505
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.5757 | 169.40M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.94 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.11 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.00 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma price target lowered to 60c from $1 at BofA - MSN
Lyell Immunopharma stock hits 52-week low at $0.58 - Investing.com India
Lyell to Highlight Vision for its Next-Generation CAR - GlobeNewswire
Lyell's IMPT-314 Cancer Therapy Shows 94% Response Rate, Plans Pivotal Trials for Lymphoma - StockTitan
Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Barclays PLC Has $332,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
State Street Corp Has $5.37 Million Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell' - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLC - Defense World
Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance
Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan
Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire
Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com
Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow
Lyell Immunopharma Reports Resignation of Board Member - Defense World
Lyell Immunopharma Director Hans bishop resigns - Investing.com
Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - The Manila Times
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):